MX2011005043A - Gotas para ojos con difluprednato para el tratamiento del edema macular. - Google Patents
Gotas para ojos con difluprednato para el tratamiento del edema macular.Info
- Publication number
- MX2011005043A MX2011005043A MX2011005043A MX2011005043A MX2011005043A MX 2011005043 A MX2011005043 A MX 2011005043A MX 2011005043 A MX2011005043 A MX 2011005043A MX 2011005043 A MX2011005043 A MX 2011005043A MX 2011005043 A MX2011005043 A MX 2011005043A
- Authority
- MX
- Mexico
- Prior art keywords
- eye drops
- administration
- difluprednate
- weeks
- volume
- Prior art date
Links
- 239000003889 eye drop Substances 0.000 title claims abstract description 134
- WYQPLTPSGFELIB-JTQPXKBDSA-N Difluprednate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CCC)[C@@]2(C)C[C@@H]1O WYQPLTPSGFELIB-JTQPXKBDSA-N 0.000 title claims abstract description 103
- 229960004875 difluprednate Drugs 0.000 title claims abstract description 81
- 208000001344 Macular Edema Diseases 0.000 title claims abstract description 63
- 206010025415 Macular oedema Diseases 0.000 title claims abstract description 63
- 201000010230 macular retinal edema Diseases 0.000 title claims abstract description 63
- 238000011282 treatment Methods 0.000 title claims description 44
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 229940012356 eye drops Drugs 0.000 claims description 130
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 23
- 239000000839 emulsion Substances 0.000 claims description 14
- 239000004359 castor oil Substances 0.000 claims description 12
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 11
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 11
- 239000004327 boric acid Substances 0.000 claims description 11
- 235000010338 boric acid Nutrition 0.000 claims description 11
- 235000019438 castor oil Nutrition 0.000 claims description 11
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 11
- 235000011187 glycerol Nutrition 0.000 claims description 11
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 11
- 239000001632 sodium acetate Substances 0.000 claims description 11
- 235000017281 sodium acetate Nutrition 0.000 claims description 11
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 claims description 11
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 10
- 229920000053 polysorbate 80 Polymers 0.000 claims description 10
- 239000004334 sorbic acid Substances 0.000 claims description 10
- 235000010199 sorbic acid Nutrition 0.000 claims description 10
- 229940075582 sorbic acid Drugs 0.000 claims description 10
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 9
- 229940068968 polysorbate 80 Drugs 0.000 claims description 9
- 229940037001 sodium edetate Drugs 0.000 claims description 9
- 229960002645 boric acid Drugs 0.000 claims description 7
- 229960001777 castor oil Drugs 0.000 claims description 7
- 229960005150 glycerol Drugs 0.000 claims description 7
- 229960004249 sodium acetate Drugs 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000004304 visual acuity Effects 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 14
- 230000003247 decreasing effect Effects 0.000 abstract description 4
- 230000002207 retinal effect Effects 0.000 abstract description 2
- 229940097575 durezol Drugs 0.000 description 22
- 210000001525 retina Anatomy 0.000 description 22
- 150000003431 steroids Chemical class 0.000 description 20
- 238000000034 method Methods 0.000 description 16
- 238000001356 surgical procedure Methods 0.000 description 16
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 13
- 230000007423 decrease Effects 0.000 description 11
- 210000001508 eye Anatomy 0.000 description 11
- 238000012360 testing method Methods 0.000 description 9
- 206010030113 Oedema Diseases 0.000 description 8
- -1 etc.) Substances 0.000 description 7
- 206010025421 Macule Diseases 0.000 description 6
- VQODGRNSFPNSQE-DVTGEIKXSA-N betamethasone phosphate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)C[C@@H]2O VQODGRNSFPNSQE-DVTGEIKXSA-N 0.000 description 5
- 229950006991 betamethasone phosphate Drugs 0.000 description 5
- 239000006196 drop Substances 0.000 description 5
- 230000000649 photocoagulation Effects 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 229960005294 triamcinolone Drugs 0.000 description 5
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 5
- 239000002260 anti-inflammatory agent Substances 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000007910 systemic administration Methods 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 description 3
- 229960002537 betamethasone Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000000695 crystalline len Anatomy 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 210000002189 macula lutea Anatomy 0.000 description 3
- 208000002780 macular degeneration Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002997 ophthalmic solution Substances 0.000 description 3
- 229940054534 ophthalmic solution Drugs 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 206010039705 Scleritis Diseases 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000004410 intraocular pressure Effects 0.000 description 2
- 238000002430 laser surgery Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010007764 Cataract subcapsular Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 1
- 206010051392 Diapedesis Diseases 0.000 description 1
- 206010015084 Episcleritis Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 206010015943 Eye inflammation Diseases 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 210000002294 anterior eye segment Anatomy 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 208000010217 blepharitis Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000011190 diabetic macular edema Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 230000000938 luteal effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 210000001210 retinal vessel Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009165924 | 2009-07-14 | ||
| PCT/JP2010/062289 WO2011007893A1 (en) | 2009-07-14 | 2010-07-14 | Eye drop with difluprednate for macular edema treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011005043A true MX2011005043A (es) | 2011-06-01 |
Family
ID=42646370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011005043A MX2011005043A (es) | 2009-07-14 | 2010-07-14 | Gotas para ojos con difluprednato para el tratamiento del edema macular. |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20110190250A1 (https=) |
| EP (1) | EP2340014B1 (https=) |
| JP (1) | JP5579079B2 (https=) |
| KR (1) | KR101689847B1 (https=) |
| CN (3) | CN107569494A (https=) |
| BR (1) | BRPI1005380A2 (https=) |
| CA (1) | CA2738151C (https=) |
| ES (1) | ES2405779T3 (https=) |
| MX (1) | MX2011005043A (https=) |
| PL (1) | PL2340014T3 (https=) |
| RU (1) | RU2572707C2 (https=) |
| TW (1) | TW201105363A (https=) |
| WO (1) | WO2011007893A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011354895B2 (en) * | 2011-01-14 | 2016-05-05 | Sds Biotech K. K. | Agri-horticultural pest control compositions comprising 4- (3-butynyl)aminopyrimidine derivatives |
| US20140018402A1 (en) * | 2011-03-30 | 2014-01-16 | Catholic University Industry Academic Cooperation Foundation | Pharmaceutical composition for preventing or treating macular degeneration |
| CN103130857A (zh) * | 2011-11-30 | 2013-06-05 | 天津金耀集团有限公司 | 二氟泼尼酯ⅱ晶型及其制备方法 |
| CN103130859B (zh) * | 2011-11-30 | 2015-12-02 | 天津金耀集团有限公司 | 二氟泼尼酯晶型i及其制备方法 |
| EP2956144B1 (en) * | 2013-02-15 | 2017-11-22 | Senju Pharmaceutical Co., Ltd. | Difluprednate emulsion composition containing zinc |
| AU2014233363B2 (en) * | 2013-03-15 | 2017-06-29 | EyePoint, Inc. | Compositions, formulations and methods for treating ocular diseases |
| JP2017528865A (ja) | 2014-06-23 | 2017-09-28 | ショット アクチエンゲゼルシャフトＳｃｈｏｔｔ ＡＧ | 板状の別個の要素を有する蓄電システム、板状の別個の要素、並びにその製造方法、及びその使用 |
| JP2018505515A (ja) | 2014-12-01 | 2018-02-22 | ショット アクチエンゲゼルシャフトＳｃｈｏｔｔ ＡＧ | シート状の独立した部材を有する蓄電システム、独立したシート状の部材、その製造方法、およびその使用 |
| EP3302382A4 (en) * | 2015-05-29 | 2019-02-20 | Allergan, Inc. | IMPLANT FOR THE TREATMENT OF OCULAR DISEASE |
| RU2661621C2 (ru) * | 2016-12-19 | 2018-07-17 | Александр Николаевич Епихин | Способ пролонгации и усиления терапевтического эффекта действия ингибиторов ангиогенеза при лечении неоваскулярных форм макулярных дегенераций |
| CN108014172A (zh) * | 2017-12-29 | 2018-05-11 | 广州仁恒医药科技股份有限公司 | 一种含有二氟泼尼酯的药物组合物及其制备方法 |
| KR20210012346A (ko) | 2019-07-25 | 2021-02-03 | 심낙범 | 미세먼지 눈꺼풀 세정스틱 |
| US20210100856A1 (en) * | 2019-09-11 | 2021-04-08 | Adverum Biotechnologies, Inc. | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept |
| HRP20260137T1 (hr) * | 2019-09-11 | 2026-03-13 | Adverum Biotechnologies, Inc. | Liječenje očnih neovaskularnih bolesti upotrebom aav2 varijanti koje kodiraju aflibercept |
| WO2026019885A1 (en) * | 2024-07-16 | 2026-01-22 | Adverum Biotechnologies, Inc. | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3781792B2 (ja) | 1993-12-27 | 2006-05-31 | 千寿製薬株式会社 | ジフルプレドナート含有点眼用懸濁液剤 |
| AU684115B2 (en) | 1993-12-27 | 1997-12-04 | Mitsubishi Chemical Corporation | Ophthalmic suspension containing diflupredonate |
| DE69807281T2 (de) * | 1997-05-14 | 2003-04-17 | Mitsubishi Chemical Corp., Tokio/Tokyo | Difluprednat enthaltende Zusammensetzungen |
| JP3410364B2 (ja) | 1997-05-14 | 2003-05-26 | 千寿製薬株式会社 | ジフルプレドナート含有組成物 |
| US20050048099A1 (en) * | 2003-01-09 | 2005-03-03 | Allergan, Inc. | Ocular implant made by a double extrusion process |
| WO2004073607A2 (en) * | 2003-02-20 | 2004-09-02 | Alcon, Inc. | Use of steroids to treat ocular disorders |
| US20050226814A1 (en) * | 2004-04-13 | 2005-10-13 | Bausch & Lomb Incorporated | Diagnostic method and kit for implantation of a sustained release drug-delivery implant with a steroid |
| WO2006017347A2 (en) * | 2004-07-12 | 2006-02-16 | Allergan, Inc. | Opthalmic compositions and methods for treating ophthalmic conditions |
| US20080233053A1 (en) * | 2005-02-07 | 2008-09-25 | Pharmalight Inc. | Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients |
| WO2007025275A2 (en) | 2005-08-25 | 2007-03-01 | Psivida Inc. | Control of induced elevated intraocular pressure |
| US20090105245A1 (en) * | 2006-12-21 | 2009-04-23 | Bingaman David P | Methods for treating macular edema and ocular angiogenesis using an anti-inflammatory agent and a receptor tyrosine kinase inhibitor |
-
2010
- 2010-07-13 TW TW099122939A patent/TW201105363A/zh unknown
- 2010-07-14 WO PCT/JP2010/062289 patent/WO2011007893A1/en not_active Ceased
- 2010-07-14 RU RU2011125640/15A patent/RU2572707C2/ru active
- 2010-07-14 CN CN201710195879.3A patent/CN107569494A/zh active Pending
- 2010-07-14 ES ES10739716T patent/ES2405779T3/es active Active
- 2010-07-14 US US13/122,467 patent/US20110190250A1/en not_active Abandoned
- 2010-07-14 MX MX2011005043A patent/MX2011005043A/es active IP Right Grant
- 2010-07-14 KR KR1020117012096A patent/KR101689847B1/ko not_active Expired - Fee Related
- 2010-07-14 JP JP2010545305A patent/JP5579079B2/ja not_active Expired - Fee Related
- 2010-07-14 CN CN2010800027502A patent/CN102170865A/zh active Pending
- 2010-07-14 BR BRPI1005380A patent/BRPI1005380A2/pt not_active Application Discontinuation
- 2010-07-14 PL PL10739716T patent/PL2340014T3/pl unknown
- 2010-07-14 CA CA2738151A patent/CA2738151C/en not_active Expired - Fee Related
- 2010-07-14 EP EP10739716.8A patent/EP2340014B1/en not_active Not-in-force
- 2010-07-14 CN CN201310288639.XA patent/CN103705524A/zh not_active Withdrawn
-
2015
- 2015-03-18 US US14/661,295 patent/US9949926B2/en not_active Expired - Fee Related
-
2018
- 2018-01-10 US US15/866,744 patent/US10092514B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2738151C (en) | 2017-02-28 |
| TW201105363A (en) | 2011-02-16 |
| RU2011125640A (ru) | 2013-08-20 |
| CN102170865A (zh) | 2011-08-31 |
| US10092514B2 (en) | 2018-10-09 |
| PL2340014T3 (pl) | 2013-09-30 |
| EP2340014B1 (en) | 2013-04-24 |
| EP2340014A1 (en) | 2011-07-06 |
| ES2405779T3 (es) | 2013-06-03 |
| KR20120040683A (ko) | 2012-04-27 |
| CA2738151A1 (en) | 2011-01-20 |
| US20180133153A1 (en) | 2018-05-17 |
| RU2572707C2 (ru) | 2016-01-20 |
| JP2012533517A (ja) | 2012-12-27 |
| US20110190250A1 (en) | 2011-08-04 |
| WO2011007893A1 (en) | 2011-01-20 |
| JP5579079B2 (ja) | 2014-08-27 |
| CN107569494A (zh) | 2018-01-12 |
| US9949926B2 (en) | 2018-04-24 |
| BRPI1005380A2 (pt) | 2016-02-10 |
| KR101689847B1 (ko) | 2016-12-26 |
| CN103705524A (zh) | 2014-04-09 |
| US20150190340A1 (en) | 2015-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10092514B2 (en) | Eye drop with difluprednate for macular edema treatment | |
| Dutra Medeiros et al. | Dexamethasone intravitreal implant for treatment of patients with persistent diabetic macular edema | |
| Harbour et al. | Pars plana vitrectomy for chronic pseudophakic cystoid macular edema | |
| Jonas | Intravitreal triamcinolone acetonide for treatment of sympathetic ophthalmia | |
| US20120136048A1 (en) | Topical, periocular, or intraocular use of tocotrienols for the treatment of ophthalmic diseases | |
| Jonas et al. | Inter-eye difference in diabetic macular edema after unilateral intravitreal injection of triamcinolone acetonide | |
| Assil et al. | Control of ocular inflammation after cataract extraction with rimexolone 1% ophthalmic suspension | |
| US8404270B2 (en) | Method of reducing incidence of intraocular pressure associated with intraocular use of corticosteroids | |
| Sandoval et al. | Evaluation of 0.4% ketorolac tromethamine ophthalmic solution versus 0.5% ketorolac tromethamine ophthalmic solution after phacoemulsification and intraocular lens implantation | |
| Steigerwalt et al. | Arteritic anterior ischemic optic neuropathy treated with intravenous prostaglandin E1 and steroids | |
| EP1633339A1 (en) | Formulations of non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis | |
| Reddy et al. | Comparative study of efficacy of topical dexamethasone 0.1% with difluprednate 0.05% in post-operative small incision cataract surgery | |
| Wagdy et al. | Intracameral Dexamethasone Injection at The End of Phaco-Vitrectomy Operation in Diabetic Patients | |
| Gama | Pseudophakic macular edema (irvine-gass syndrome): has the treatment changed? | |
| Amer et al. | Role of corneal collagen cross-linkage in the treatment of keratoconus | |
| Edema | OZURDEX®(Dexamethasone Intravitreal Implant) 0.7 mg as Initial Therapy in Pseudophakic Patients With Diabetic Macular Edema, Macular Edema Following Retinal Vein Occlusion, and Noninfectious Posterior Segment Uveitis: A Case-Based Discussion | |
| Marc et al. | Ocular toxicity of topical indomethacin eye drops | |
| Gama | Pseudophakic Macular Edema (Irvine-Gass syndrome): Has the Treatment Changed?. MJ Opht. 1 (1): 004 | |
| Gianni Belcaro et al. | Arteritic anterior ischemic optic neuropathy treated with intravenous prostaglandin E | |
| ZA200509532B (en) | Formulations or non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis | |
| JP2007056012A (ja) | 軟膏様組成物を用いた後眼部組織への非侵襲性ドラッグデリバリーシステム | |
| JPWO2000076454A1 (ja) | 眼科治療用組成物および脳中枢病変治療用組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |